Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 15/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2190879 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2MEN1KMT2ANPC1TP53 | |
| SCHEMBL15427027 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1KMT2ANPC1TP53 | |
| SCHEMBL2190710 | 0.85 | L3MBTL1 (0.62) | SMN1; SMN2MEN1KMT2ANPC1TP53 | |
| SCHEMBL2190712 | 0.85 | L3MBTL1 (0.62) | SMN1; SMN2MEN1KMT2ANPC1TP53 | |
| SCHEMBL12507422 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2MEN1KMT2ANPC1TP53 | |
| SCHEMBL2191264 | 0.78 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2191268 | 0.78 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14164036 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL15427126 | 0.78 | SMN1; SMN2 (0.75) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2190882 | 0.77 | IDO1 (0.59) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064207-B1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORP (US) | 2013-11-06 | — | — | EP | claimed |
| US-8377976-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-02-19 | — | — | US | claimed |
| US-20110172279-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-07-14 | — | — | US | claimed |
| EP-2064207-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080125470-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-29 | — | — | US | claimed |
| WO-2008036642-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| EP-2064207-B1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORP (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8377976-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110172279-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-07-14 | — | — | US | disclosed |
| US-20080125470-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172279-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | SMN1; SMN2 3241/4885MEN1 2391/4885KMT2A 675/4885 |
| US-20080125470-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | SMN1; SMN2 3241/4885MEN1 2391/4885KMT2A 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.